JP2009536036A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536036A5
JP2009536036A5 JP2009510114A JP2009510114A JP2009536036A5 JP 2009536036 A5 JP2009536036 A5 JP 2009536036A5 JP 2009510114 A JP2009510114 A JP 2009510114A JP 2009510114 A JP2009510114 A JP 2009510114A JP 2009536036 A5 JP2009536036 A5 JP 2009536036A5
Authority
JP
Japan
Prior art keywords
cells
epitope
autoreactive
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009510114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536036A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/068304 external-priority patent/WO2007131210A2/en
Publication of JP2009536036A publication Critical patent/JP2009536036A/ja
Publication of JP2009536036A5 publication Critical patent/JP2009536036A5/ja
Withdrawn legal-status Critical Current

Links

JP2009510114A 2006-05-05 2007-05-04 Ｔ細胞ワクチン Withdrawn JP2009536036A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74661106P 2006-05-05 2006-05-05
US74790306P 2006-05-22 2006-05-22
PCT/US2007/068304 WO2007131210A2 (en) 2006-05-05 2007-05-04 T-cell vaccine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013163134A Division JP6000205B2 (ja) 2006-05-05 2013-08-06 Ｔ細胞ワクチン
JP2016003678A Division JP2016053090A (ja) 2006-05-05 2016-01-12 Ｔ細胞ワクチン

Publications (2)

Publication Number Publication Date
JP2009536036A JP2009536036A (ja) 2009-10-08
JP2009536036A5 true JP2009536036A5 (enExample) 2013-09-19

Family

ID=38668612

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009510114A Withdrawn JP2009536036A (ja) 2006-05-05 2007-05-04 Ｔ細胞ワクチン
JP2013163134A Expired - Fee Related JP6000205B2 (ja) 2006-05-05 2013-08-06 Ｔ細胞ワクチン
JP2016003678A Withdrawn JP2016053090A (ja) 2006-05-05 2016-01-12 Ｔ細胞ワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013163134A Expired - Fee Related JP6000205B2 (ja) 2006-05-05 2013-08-06 Ｔ細胞ワクチン
JP2016003678A Withdrawn JP2016053090A (ja) 2006-05-05 2016-01-12 Ｔ細胞ワクチン

Country Status (12)

Country Link
US (1) US20100003228A1 (enExample)
EP (3) EP2016414B1 (enExample)
JP (3) JP2009536036A (enExample)
AU (1) AU2007247869B2 (enExample)
CA (1) CA2651328A1 (enExample)
DK (2) DK2016414T3 (enExample)
ES (2) ES2552667T3 (enExample)
IL (1) IL195115A (enExample)
NZ (1) NZ572644A (enExample)
PL (2) PL2016414T3 (enExample)
PT (2) PT2016414E (enExample)
WO (1) WO2007131210A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL398077A1 (pl) * 2012-02-10 2012-08-27 Krzysztof Selmaj Kompozycja farmaceutyczna oraz zastosowanie kompozycji do wytwarzania leku, do podawania naskórnego, do leczenia stwardnienia rozsianego
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN105992950A (zh) * 2013-12-19 2016-10-05 欧普萨治疗股份有限公司 T 细胞表位表达谱分析、制备 t 细胞组合物以及治疗疾病的方法
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
WO2016037123A2 (en) 2014-09-05 2016-03-10 Opexa Therapeutics, Inc. Compositions and methods for treating b cell mediated autoimmune disorders
US10231033B1 (en) 2014-09-30 2019-03-12 Apple Inc. Synchronizing out-of-band content with a media stream
AU2018206015B2 (en) 2017-01-06 2019-05-30 Eutilex Co., Ltd. Anti-human 4-1 BB antibodies and use thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4608365A (en) * 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
US4677061A (en) * 1984-10-19 1987-06-30 Genetic Systems Corporation T-cell lymphocyte subset monitoring of immunologic disease
US4902680A (en) * 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
US4898857A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Treating control nervous system diseases
US4898856A (en) * 1984-10-29 1990-02-06 Chaovanee Aroonsakul Method for treating central nervous system diseases
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
CA1296622C (en) * 1986-08-12 1992-03-03 Jeffrey E. Anderson Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5039660A (en) * 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5861164A (en) * 1989-03-21 1999-01-19 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6007815A (en) * 1989-03-21 1999-12-28 The Immune Response Corporation Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations
US6221352B1 (en) * 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5837246A (en) * 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5612035A (en) * 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5298396A (en) * 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
WO1992001044A1 (en) * 1990-07-06 1992-01-23 Allergene, Inc. Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5545716A (en) * 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
WO1994020120A1 (en) * 1993-03-12 1994-09-15 Cellcor, Inc. In vitro assay measuring degree of activation of immune cells
US5494899A (en) * 1993-04-07 1996-02-27 Oklahoma Medical Research Foundation Selective regulation of B lymphocyte precursors by hormones
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
JPH09510437A (ja) * 1993-12-28 1997-10-21 カイロン ミモトープス プロプライエトリー リミテッド Ｔ細胞エピトープ
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6410518B1 (en) * 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5723503A (en) * 1994-09-28 1998-03-03 Thomas Jefferson University Biological treatment for rheumatoid arthritis
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
US6033661A (en) * 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
US6096314A (en) * 1994-10-07 2000-08-01 Yeda Research And Development Co. Ltd. Peptides and pharmaceutical compositions comprising them
EP1172376A1 (en) * 1994-11-18 2002-01-16 Neurocrine Biosciences, Inc. Peptide analogues at position 91 of human myelin basic protein for treatment of multiple sclerosis
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5869057A (en) * 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
SE9502921D0 (sv) * 1995-08-23 1995-08-23 Astra Ab New compounds
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US5750356A (en) * 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5849886A (en) * 1996-07-10 1998-12-15 Oy Aboatech Ab Extraction of myelin basic protein
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
KR20000049096A (ko) * 1996-10-11 2000-07-25 린다 에스. 스티븐슨 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법
US6054292A (en) * 1997-07-18 2000-04-25 Incyte Pharmaceuticals, Inc. T-cell receptor protein
US20020009448A1 (en) * 1997-09-19 2002-01-24 Leslie P. Weiner T-cell vaccination for the treatment of multiple sclerosis
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20020001841A1 (en) * 1998-06-26 2002-01-03 Keld Kaltoft Continuous t-cell lines
AU774952B2 (en) * 1999-02-23 2004-07-15 Baylor College Of Medicine T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection
US6187750B1 (en) * 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
SI1311542T1 (sl) * 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
JP2004535785A (ja) * 2000-11-22 2004-12-02 ディアデクサス インコーポレーテッド 乳房特異的遺伝子およびタンパク質に関する組成物および方法
US20030078347A1 (en) * 2001-08-28 2003-04-24 General Electric Company Triazine compounds, polymers comprising triazine structural units, and method
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
EP1444330A1 (en) * 2001-11-07 2004-08-11 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
US20050181459A1 (en) * 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
CA2542668C (en) * 2003-10-17 2014-04-29 Baylor College Of Medicine A method for increasing cd8+ cytotoxic t cell reponses and for treating multiple sclerosis
CN101711861A (zh) * 2003-10-31 2010-05-26 不列颠哥伦比亚大学 细菌毒力因子及其用途
WO2005074579A2 (en) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Peptide mixtures with immunomodulatory activity

Similar Documents

Publication Publication Date Title
Gao et al. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ T cell responses post SARS-CoV-2 infection
Yin et al. HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM–mediated half-lives
Mullen et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria
JP2009536036A5 (enExample)
Kamala Hock immunization: a humane alternative to mouse footpad injections
US20220293215A1 (en) Systems and methods for mhc class ii epitope prediction
ES2431891T3 (es) Antígenos de micobacterias
BR112021005702A2 (pt) método para selecionar neoepítopos
Voigt et al. Unique glandular ex-vivo Th1 and Th17 receptor motifs in Sjögren's syndrome patients using single-cell analysis
Dijkman et al. A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG
CN116056722A (zh) Sars-cov-2疫苗
CN101724023B (zh) 结核分枝杆菌抗原限制性表位肽
McMurry et al. Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice
Aebischer Leishmania spp. proteome data sets: a comprehensive resource for vaccine development to target visceral leishmaniasis
Berrêdo-Pinho et al. Proteomic profile of culture filtrate from the Brazilian vaccine strain Mycobacterium bovis BCG Moreau compared to M. bovis BCG Pasteur
DK2420833T3 (en) T-cell vaccine
Adler et al. PBMC transcription profiles of pigs with divergent humoral immune responses and lean growth performance
Ernst et al. Meeting report: NIH workshop on the tuberculosis immune epitope database
EP2696891A1 (en) New vaccines for prevention and treatment of tuberculosis
Pritam et al. Screening of potential antigens from whole proteome and development of multi-epitope vaccine against Rhizopus delemar using immunoinformatics approaches
de Jong et al. PAN–DR‐Binding Hsp60 self epitopes induce an interleukin‐10–mediated immune response in rheumatoid arthritis
WO2007005627A8 (en) Tuberculosis antigen detection assays and vaccines
Song et al. A synthetic SARS-CoV-2-derived T-cell and B-cell peptide cocktail elicits full protection against lethal Omicron BA. 1 infection in H11-K18-hACE2 mice
Mustafa In silico binding predictions for identification of HLA-DR-promiscuous regions and epitopes of Mycobacterium tuberculosis protein MPT64 (Rv1980c) and their recognition by human Th1 cells
Yu et al. A Novel Tuberculosis Antigen Identified from Human Tuberculosis Granulomas*[S]